The effect of acupuncture at Yanglingquan and Zusanli combined with intravenous and inhalation general anesthesia on stress response and postoperative gastrointestinal function recovery in patients undergoing laparoscopic cholecystectomy

注册号:

Registration number:

ITMCTR2025001327

最近更新日期:

Date of Last Refreshed on:

2025-07-02

注册时间:

Date of Registration:

2025-07-02

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

阳陵泉透刺足三里配合静吸复合全麻对腹腔镜胆囊切除术患者应激反应与术后胃肠功能恢复的影响

Public title:

The effect of acupuncture at Yanglingquan and Zusanli combined with intravenous and inhalation general anesthesia on stress response and postoperative gastrointestinal function recovery in patients undergoing laparoscopic cholecystectomy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

阳陵泉透刺足三里配合静吸复合全麻对腹腔镜胆囊切除术患者应激反应与术后胃肠功能恢复的影响

Scientific title:

The effect of acupuncture at Yanglingquan and Zusanli combined with intravenous and inhalation general anesthesia on stress response and postoperative gastrointestinal function recovery in patients undergoing laparoscopic cholecystectomy

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李爽

研究负责人:

张晓强

Applicant:

Shuang Li

Study leader:

Xiaoqiang Zhang

申请注册联系人电话:

Applicant telephone:

+86 183 5673 9886

研究负责人电话:

Study leader's telephone:

+86 133 0967 0321

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

cool1860@126.com

研究负责人电子邮件:

Study leader's E-mail:

zxqahl@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

安徽省亳州市蒙城县城关社区商城东路282号

研究负责人通讯地址:

安徽省亳州市蒙城县城关社区商城东路282号

Applicant address:

282 Shopping Mall Road East Chengguan Community Mengcheng County Bozhou Anhui China

Study leader's address:

282 Shopping Mall Road East Chengguan Community Mengcheng County Bozhou Anhui China

申请注册联系人邮政编码:

Applicant postcode:

233500

研究负责人邮政编码:

Study leader's postcode:

233500

申请人所在单位:

蒙城县第一人民医院

Applicant's institution:

Mengcheng County No. 1 People's Hospital

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

(2025)伦审第(MYL2025006)号

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

蒙城县第一人民医院医学伦理委员会

Name of the ethic committee:

Institutional Review Board of Mengcheng NO.1 People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025/3/14 0:00:00

伦理委员会联系人:

陈晓林

Contact Name of the ethic committee:

Xiaolin Chen

伦理委员会联系地址:

安徽省亳州市蒙城县城关社区商城东路282号

Contact Address of the ethic committee:

282 Shopping Mall Road East Chengguan Community Mengcheng County Bozhou Anhui China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 558 762 3591

伦理委员会联系人邮箱:

Contact email of the ethic committee:

274138885@qq.com

研究实施负责(组长)单位:

蒙城县第一人民医院

Primary sponsor:

Mengcheng County No. 1 People's Hospital

研究实施负责(组长)单位地址:

安徽省亳州市蒙城县城关社区商城东路282号

Primary sponsor's address:

282 Shopping Mall Road East Chengguan Community Mengcheng County Bozhou Anhui China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

安徽

市(区县):

亳州

Country:

China

Province:

Anhui

City:

Bozhou

单位(医院):

蒙城县第一人民医院

具体地址:

安徽省亳州市蒙城县城关社区商城东路282号

Institution
hospital:

Mengcheng County No. 1 People's Hospital

Address:

282 Shopping Mall Road East Chengguan Community Mengcheng County Bozhou Anhui China

经费或物资来源:

安徽省卫生健康科研项目

Source(s) of funding:

Anhui Provincial Health Research Project

研究疾病:

胆囊结石

研究疾病代码:

Target disease:

Gallstone

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

通过临床试验,观察阳陵泉透刺足三里配合静吸复合全麻对腹腔镜胆囊切除术患者应激反应与术后胃肠功能恢复的影响

Objectives of Study:

Through clinical trials observe the effect of acupuncture at Yanglingquan and Zusanli combined with intravenous and inhalation general anesthesia on stress response and postoperative gastrointestinal function recovery in patients undergoing laparoscopic cholecystectomy

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1.年龄18~65岁; 2.BMI:18-30 kg/m2; 3.ASA I或Ⅱ级; 4.择期行腹腔镜胆囊切除术的患者; 5.所有患者均签署知情同意书。

Inclusion criteria

1. Age range: 18 to 65 years old; 2.BMI18-30 kg/m2 3. ASA Level I or II; 4. Patients undergoing elective laparoscopic cholecystectomy; 5. All patients sign informed consent forms.

排除标准:

1.既往有胃肠疾病史的患者; 2.既往有中枢神经系统疾病或精神疾病的患者; 3.针刺穴位部位及附近皮肤有感染者; 4.术前有严重心、肺、肝、肾脏疾病及胃肠道疾病如便秘等患者; 5.入组24 h前服用止吐、镇静类药物。

Exclusion criteria:

1. Patients with a history of gastrointestinal diseases; 2. Patients with previous central nervous system or psychiatric disorders; 3. There are infected individuals in the acupuncture point area and nearby skin; 4. Patients with severe heart lung liver kidney diseases and gastrointestinal diseases such as constipation before surgery; 5. Take antiemetic and sedative drugs 24 hours before enrollment.

研究实施时间:

Study execute time:

From 2025-04-15

To      2028-04-15

征募观察对象时间:

Recruiting time:

From 2025-04-15

To      2026-04-15

干预措施:

Interventions:

组别:

合谷内关组(B组)

样本量:

30

Group:

Hegu Neiguan Group (Group B)

Sample size:

干预措施:

针刺合谷和内关穴

干预措施代码:

Intervention:

acupuncture at Hegu and Neiguan

Intervention code:

组别:

对照组(C组)

样本量:

30

Group:

Control group (Group C)

Sample size:

干预措施:

不进行针灸操作

干预措施代码:

Intervention:

No acupuncture

Intervention code:

组别:

阳陵泉透刺足三里组(A组)

样本量:

30

Group:

Yanglingquan Zusanli Group (Group A)

Sample size:

干预措施:

阳陵泉透刺足三里穴位

干预措施代码:

Intervention:

acupuncture at Yanglingquan and Zusanli

Intervention code:

样本总量 Total sample size : 90

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

安徽

市(区县):

亳州

Country:

China

Province:

Anhui

City:

Bozhou

单位(医院):

蒙城县第一人民医院

单位级别:

三级

Institution/hospital:

Mengcheng County No. 1 People's Hospital

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

胃泌素

指标类型:

主要指标

Outcome:

gastrin

Type:

Primary indicator

测量时间点:

麻醉前、术后24 h

测量方法:

血液

Measure time point of outcome:

before anesthesia and 24 hours after surgery

Measure method:

blood

指标中文名:

皮质醇

指标类型:

次要指标

Outcome:

cortisol

Type:

Secondary indicator

测量时间点:

麻醉前、术后24 h

测量方法:

Measure time point of outcome:

before anesthesia and 24 hours after surgery

Measure method:

指标中文名:

术后首次排气排便时间

指标类型:

次要指标

Outcome:

Time of first postoperative exhaust and defecation

Type:

Secondary indicator

测量时间点:

术后

测量方法:

Measure time point of outcome:

postoperative

Measure method:

指标中文名:

去甲肾上腺素

指标类型:

次要指标

Outcome:

norepinephrine

Type:

Secondary indicator

测量时间点:

麻醉前、术后24 h

测量方法:

Measure time point of outcome:

before anesthesia and 24 hours after surgery

Measure method:

指标中文名:

恶心呕吐

指标类型:

次要指标

Outcome:

Nausea and vomiting

Type:

Secondary indicator

测量时间点:

术后6、24、48 h

测量方法:

Measure time point of outcome:

Postoperative 6, 24, and 48 hours

Measure method:

指标中文名:

肾上腺素

指标类型:

次要指标

Outcome:

adrenaline

Type:

Secondary indicator

测量时间点:

麻醉前、术后24 h

测量方法:

Measure time point of outcome:

before anesthesia and 24 hours after surgery

Measure method:

指标中文名:

血氧饱和度、平均动脉压、心率

指标类型:

次要指标

Outcome:

SpO2、MAP 、HR

Type:

Secondary indicator

测量时间点:

麻醉前( T0) 、气腹后30min ( T1) 、术毕即刻( T2) 、术后6 h ( T3)

测量方法:

Measure time point of outcome:

Before anesthesia (T0), 30 minutes after pneumoperitoneum (T1), immediately after surgery (T2), and 6 hours after surgery (T3)

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 18
Min age years
最大 65
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究团队成员使用“随机数字表”的方法产生随机序列。

Randomization Procedure (please state who generates the random number sequence and by what method):

Research team members use the method of "random number table" to generate random sequence.

盲法:

Blinding:

none

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

ResMan临床试验公共管理平台“http://www.medresman.org.cn/uc/index.aspx”

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan Clinical Trial Public Management Platform “http://www.medresman.org.cn/uc/index.aspx”

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above